Special Edition: Time in Range: Medication Management – March 2023
Diabetes Core Update
00:00
Is There a Need for Cardio Renal Risk Reduction?
If we can remove the need for cardio renal risk reduction from the table and that's not a factor, the guideline stress really focusing on achieving individualized glysemic and weight management goals. The guidelines also acknowledge that we should be thinking about potentially adding on medications indicated for the treatment of obesity or even considering metabolic surgery when appropriated indicated. Dr. Scholnick: I have to mention our recently approved dual GLP one GIP receptor agonist, herzepitide. We've seen some dramatic weight loss in the few people I've seen on this medication.
Transcript
Play full episode
